Viracta Therapeutics
Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.
Top Regions
Top Stages
1 past transactions
Sunesis Pharmaceuticals
Acquisition in 2020
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate, vecabrutinib, is a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. Additionally, Sunesis is advancing SNS-510, which is in preclinical studies for various tumor types, alongside partnered programs such as TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer quinolone derivative. The company has established collaborations, including an agreement with Biogen Idec MA, Inc. for small molecule BTK inhibitors and a licensing agreement with Takeda Pharmaceutical Company Limited for preclinical PDK1 inhibitors. Founded in 1998 and headquartered in South San Francisco, California, Sunesis Pharmaceuticals is committed to innovative approaches in the ongoing fight against cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.